Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

Exclusion Criteria

• •Unable to sign informed consent
• •Contraindications to any of the components of the polypill
• •Hemorrhagic stroke
• •Severe cognitive impairment/dementia or severe global disability limiting the capacity of self-care
• •Severe congestive cardiac failure (NYHA III-IV)
• •Severe renal disease, eGFR \<30ml/min/1.73m2), renal dialysis; awaiting renal transplant or transplant recipient
• •Cancer diagnosis or treatment in past 2 years
• •Need for oral anticoagulation at the time of randomization or planned in the future months;
• •Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation)
• •Nursing/pregnant mothers
• •Do not agree to the filing, forwarding and use of his/her pseudonymized data.